Fecal calprotectin

Accurate diagnosis and classification affect treatment choices and risks—misdiagnosis can lead to unnecessary immunosuppression, while misclassification can under-recognize severe or proximal disease that needs different...

A simple blood test (CRP) that's already used in IBD care might help predict which Crohn's patients with C. difficile coinfection are more likely to need intestinal surgery, enabling earlier attention or monitoring.

Malnutrition is common in IBD and linked to worse quality of life and outcomes. Validating a standardized GLIM approach could help clinicians identify and treat malnutrition earlier and more consistently in people with...

Parents and clinicians often worry about liver disease when children are diagnosed with Crohn's. This study suggests advanced liver fibrosis is uncommon at diagnosis, but elastography and fibrotic biomarkers can be...

This report describes early human evidence that an oral, gut-targeted PDE4 inhibitor (PALI-2108) may reduce intestinal inflammation and improve endoscopic findings in people with Crohn's disease and ulcerative colitis —...

Early-phase data suggest PALI-2108 reaches the ileum and colon and produced rapid reductions in endoscopic inflammation and fecal calprotectin in small Phase 1b cohorts—results that could matter if confirmed in larger...

Patients and clinicians worry isotretinoin might trigger flares in people with existing IBD. This study suggests that among patients with stable, well-controlled Crohn's or UC, isotretinoin did not generally worsen...

Identifying a blood biomarker that appears before symptoms could help find people at higher risk for Crohn’s disease and improve understanding of early disease processes. This could inform earlier monitoring or future...

A blood biomarker that predicts anti-TNF response could help people with IBD and their clinicians choose the right biologic sooner, avoiding ineffective treatment. This study reports that lower baseline serum oncostatin...

The study links lower vitamin D and higher TNF‑alpha with greater UC severity and with each other, suggesting these measurable biomarkers may reflect inflammation in ulcerative colitis.

The study explores whether people with UC in deep histologic remission can reduce or stop maintenance medications without losing remission — a question many patients and clinicians face because of medication costs, side...

IUS with the IBUS‑SAS score may offer a reliable, noninvasive way to monitor Crohn’s disease activity that correlates with clinical scores and biomarkers and aligns well with CT/MRI for most findings.

This study aims to measure how much time people with ulcerative colitis spend with objectively uncontrolled inflammation and to compare real-world outcomes of different initial advanced-therapy choices and...

If reliable, blood biomarkers that track IBD activity could help noninvasively follow children with Crohn’s disease or ulcerative colitis. This study suggests MMP-9 and TIMP-1 change with disease course but did not show...

A blood biomarker that reflects transmural inflammation could help monitor small-bowel Crohn’s disease noninvasively and might predict risk of rehospitalization.

The trial tests a naturally derived oral supplement (WPMDE2) in patients with ulcerative colitis, measuring symptoms, inflammatory markers, and quality of life—outcomes that matter to people living with IBD. Early-phase...

This registry-based study compares early control of inflammation on conventional therapy versus escalating to advanced treatments in newly diagnosed ulcerative colitis, using CRP and fecal calprotectin to define...

If confirmed, an existing diabetes drug class (SGLT2 inhibitors) could offer an adjunct anti-inflammatory option for people with mild-to-moderate ulcerative colitis and might affect symptoms, biomarkers, and quality of...

Fusing blood tests, CT enterography radiomics, and deep-learning analysis of deep small-bowel endoscopy images may improve detection of active small-bowel Crohn’s disease — a common clinical challenge because many...

Researchers are investigating whether a specific gut bacterium (Pilosibacter rotomagensis) is linked to lower intestinal inflammation after surgery for ileal Crohn's disease. If true, this could point toward new...

This trial suggests a structured whole-food diet may reduce subclinical intestinal inflammation (measured by fecal calprotectin) in asymptomatic children and young adults with Crohn's disease—offering a non-formula,...

Early human data suggest PALI-2108 reaches intestinal tissue and produced short-term clinical, endoscopic, and biomarker changes in very small Phase 1 cohorts, supporting larger Phase 2 trials that could determine if...

Early Phase 1 findings suggest a gut-targeted PDE4 prodrug may engage its target in diseased tissue and produce early improvements in symptoms, endoscopy, and tissue inflammation — findings that, if confirmed in Phase 2,...

Conference analyses describe how subcutaneous infliximab performs after stopping IV treatment and when compared with IV infliximab for ileal/ileocolonic Crohn's — information that could affect treatment decisions for...

This study links higher mucosal PD-L1 expression to active IBD and routine disease activity measures, suggesting the PD-1/PD-L1 immune checkpoint may be involved in intestinal inflammation and could be a biomarker or...

Noninvasive fecal tests can help detect intestinal inflammation without repeated endoscopy and support treat-to-target care. Better biomarkers could mean earlier treatment changes and less invasive monitoring for people...

If you or your child is starting exclusive enteral nutrition (EEN) for pediatric Crohn’s disease, this review explains why outcomes vary and what tests and research might help predict who will benefit.

People with IBD often have sleep problems and ongoing inflammation; melatonin could help both sleep and clinical disease activity, which may improve quality of life. The review suggests potential benefit but is not...

Identifying people at very early, preclinical stages of Crohn’s disease could allow enrollment in prevention trials and earlier intervention. Faecal calprotectin may help select higher‑risk first‑degree relatives for...

Berries are a familiar, dietary source of anti-inflammatory bioactive compounds that might help reduce intestinal inflammation and improve biomarkers relevant to IBD. Patients often seek safe, complementary strategies...

Microbiome patterns in this study were linked to inflammation (fecal calprotectin) and higher chance of needing treatment escalation. If validated, enterotype stratification could help predict disease course or tailor...

Vitamin D deficiency is common in people with IBD and can affect bone health and possibly immune function.

Diet is a potentially modifiable factor that could affect symptoms, inflammation, and the gut microbiome in ulcerative colitis; this trial aims to test whether a modified Mediterranean diet added to standard therapy...

Shortening ustekinumab dosing intervals raised drug levels and was associated with high rates of steroid-free clinical remission in this small prospective IBD cohort, offering a practical option for patients who lose...

This trial examines whether a blueberry-rich supplement can change inflammation, the microbiome, and intestinal barrier function in people with chronic colitis — topics many with IBD care about because diet and the...

If gut microbes produce LPC/LPA that are linked to chronic abdominal pain, it could point to new biomarker or microbiome-targeted approaches for unexplained pain in IBD patients whose inflammation is quiet or minimal.

A multimodal, simpler activity score could improve practical disease monitoring when full ileocolonoscopy isn’t possible and help standardize treat-to-target practice across centers.

A microbiome-targeted, food-grade supplement could offer a non-immunosuppressive option for people with mild-to-moderate ulcerative colitis who remain inflamed or want to delay immunosuppressive/biologic therapy. The...

Hospitalized patients with acute severe ulcerative colitis often need rescue therapy to avoid colectomy.

Understanding how individual diet and microbiome patterns relate to disease activity could help create personalized dietary approaches for children with Crohn's disease and improve monitoring using home fecal...

Long-term real-world data on filgotinib help patients and clinicians understand how durable benefits and risks are over 2 years, including likelihood of staying on therapy and changes in inflammation markers.

Fecal calprotectin is commonly used to monitor IBD activity. If bowel prep raises calprotectin modestly, that could affect how post-procedure results are interpreted and avoid unnecessary treatment changes.

This study provides real-world evidence about using upadacitinib as a maintenance therapy in children with refractory Crohn’s disease — a group with limited treatment options.

Dietary approaches that reduce gut inflammation could offer a low‑risk option to help manage symptoms and biomarkers in Crohn’s disease. This trial specifically tests a catered anti‑inflammatory diet and measures fecal...

Noninvasive fecal biomarkers are widely used to track IBD activity. Knowing whether different FC assays give comparable results and whether combining tests adds value affects how patients and clinicians interpret...

Early prediction of who will not respond to infliximab could help clinicians avoid prolonged ineffective treatment, enabling earlier reassessment and changes in therapy as part of treat-to-target care.

Many people with IBD have ongoing IBS-like symptoms despite little or no intestinal inflammation. This project targets brain–gut and autonomic mechanisms that might explain symptom persistence and tests a non-drug...

Mucosal colonisation by adherent‑invasive E. coli has been implicated in Crohn’s disease for some patients; this study suggests FMT can change the mucosal microbiome and clear AIEC in a small pilot cohort, which could be...